Edwards to pursue regulatory approval after FTC action to block JenaValve deal

Edwards Lifesciences (EW) announced that the U.S. Federal Trade Commission moved to block the company’s proposed acquisition of JenaValve Technology. “Edwards disagrees with FTC’s decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation. The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR. AR is a deadly and progressive disease that affects a significant and growing number of patients, many of whom currently have limited treatment options. Edwards intends to continue to pursue regulatory approval of the acquisition and estimates a final determination by the end of Q1 2026,” the company stated.